Veraxa Biotech AG - Post de-SPAC reported net income of -$0.03M for the quarter ended Dec 2025. This income statement covers 2 quarters of results from Dec 2024 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2024 | Dec2025 |
|---|---|---|
| Operating items | ||
| Selling, General & AdministrativeSG&A | 0.01M | |
| Operating ExpensesOpex | 0.01M | |
| Net income details | ||
| Profit After TaxPAT | -0.03M | |
| Additional items | ||
| Shares Outstanding | 14.05M | 14.47M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 14.05M | 14.47M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 14.05M | 14.47M |